PerkinElmer introduces the industry's first cell analysis solution to streamline research and manufacturing of cell and gene therapies

PerkinElmer introduces the industry's first cell analysis solution to streamline research and manufacturing of cell and gene therapies

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the Cellaca® PLX Image Cytometry System, a unique benchtop platform that enables researchers to assess multiple critical quality attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity.

The state-of-the-art Cellaca PLX system, developed by the company's Nexcelom division, combines world-class imaging cytometer hardware, software, validated consumables and traceable data reporting in one system, without the need for complex calibration procedures or intensive training requirements. To further optimize the customer experience, optimized Reagent kits with validated antibodies from PerkinElmer’s BioLegend Business are also part of the proprietary solution.

The new offering provides researchers with expanded options for CQA analysis of cell samples, beyond flow cytometry and staining methods, which have historically required a variety of different instruments and analytical methods. By combining these features, researchers can now detect multiple markers simultaneously (multiplexing) and perform immunophenotyping and viability testing in seconds using an easy-to-use, modern interface.

“Pharmaceutical companies have invested heavily in cell and gene therapy, but they are struggling to evaluate the complex cell samples required to meet the immense scientific demands and stringent regulations in their research and manufacturing processes,”

Alan Fletcher, senior vice president, life sciences, PerkinElmer.

“While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be particularly useful for researchers working in CAR T-cell therapy who want to optimize their immune cell phenotyping for downstream processes.”

PerkinElmer's Nexcelom unit is a leading provider of automated cell counting technology and image cytometry products for cell analysis, including original and widely used products Cellaca® MX High throughput automatic cell counter. Learn more about the new platform and other image cytometry instruments and reagents at BioProcessing International East, September 27-30 in Boston, where PerkinElmer will be showcasing the latest innovations from its extensive life science and cell and gene therapy portfolios at booths 625 and 631. Product demonstrations can be scheduled Here.

About PerkinElmer

PerkinElmer is a leading global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose diseases, discover new and more personalized medicines, monitor the safety and quality of our food, and drive excellence in environmental and applied analytics. With 85 years of experience advancing science and a mission to innovate for a healthier world, our dedicated team of more than 16,000 employees works closely with business, government, academic and healthcare customers to provide reagents, tests, instrumentation, automation, informatics and strategy services that accelerate workflows, deliver actionable insights and improve decision-making support.

We are also strongly committed to good corporate social responsibility through our dynamic ESG and sustainability programs. The company reported 2021 sales of approximately $5.0 billion, serves customers in 190 countries and is a component of the S&P 500 index. For more information, see www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram And Youtube.